1. CNS administration of XPro1595 does not affect TMEV-induced acute seizure frequency and intensity.
CNS administration of XPro1595 does not affect TMEV-induced acute seizure frequency and intensity. (A) Slow infusion of XPro1595 (10 mg/kg) at 0, 2, 4, and 6 dpi into the left lateral ventricle using a surgically implanted guide cannula did not reduce average seizure frequency or severity (n = 12, XPro1595; n = 11, vehicle). Each circle represents an individual mouse, and the horizontal line shows average number of seizures per group per acute seizure period (3–8 dpi). (B) Average seizure burden corresponding to each stage of modified Racine scale for generalized tonic-clonic seizures shows no difference between vehicle- and XPro1595-treated TMEV-infected mice. Only those mice that had acute seizures are included in this analysis. (C) The surgical placement of the guide cannula into the left lateral ventricle was confirmed by i.c.v. infusion of 0.1% Evans blue dye at 9 dpi in all TMEV-infected mice treated with either XPro1595 or vehicle. The panel shows an example of a diffusion of the dye into the ventricular system.
Dipan C. Patel et al. eNeuro 2017;4:ENEURO
©2017 by Society for Neuroscience